ArticleJournal of fungi (Basel, Switzerland)2022
Terbinafine Resistance in Dermatophytes: A French Multicenter Prospective Study.
Article in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06400056 (Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Pooled it
- Emerging Terbinafine Resistant Trichophyton Dermatophytosis, Testing Options and Alternative Treatments: A Systematic Review.The Australasian journal of dermatology · 2025Pooled it
- Pooled it
- Emerging Global Patterns of Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Dermatophytosis: An Update on Global Epidemiology.Journal of fungi (Basel, Switzerland) · 2026Review
- Therapeutic Challenges in Case of Trichophyton indotineae Dermatophytosis, Singapore, 2025.Emerging infectious diseases · 2026Article
- The emergence of superficial dermatophytosis due toJournal of clinical microbiology · 2026Article
- Molecular analysis of squalene epoxidase gene mutations in Trichophyton rubrum from clinical onychomycosis samples in South Korea.Scientific reports · 2026Article
- Sensitivity of Dermatophytes to Terbinafine: World Experience and Recent Findings from Kazakhstan.Antibiotics (Basel, Switzerland) · 2026Article
- Rising antifungal resistance inFrontiers in microbiology · 2026Review
- Global Emergence ofInfection and drug resistance · 2026Review
- Recalcitrant dermatophytosis due toMedical mycology case reports · 2025Article
- Emerging antifungal resistance inEmerging microbes & infections · 2025Article
- The First Isolation of Multiple Antifungal-Drug-Resistant Trichophyton Rubrum in China and the Novel Resistance Mechanism.Mycoses · 2025Article
- Synthesis and Biological Evaluation of Novel 2-(Piperidin-4-yl)-1,2,3,4-tetrahydroisoquinoline and 2-(Piperidin-4-yl)decahydroisoquinoline Antimycotics.Archiv der Pharmazie · 2025Article
- Shifting etiological agents of dermatophytosis: a molecular epidemiological study from Iran.Iranian journal of microbiology · 2025Article
- Evaluation of Clinical Studies of Patients With Dermatophyte Infections Caused by Trichophyton indotineae: Treatment Response and Resistance to Antifungal Medications.Dermatology practical & conceptual · 2025Review
- Integrating Machine Learning and Molecular Methods forPathogens (Basel, Switzerland) · 2025Article
- National Belgian Study on Terbinafine Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Epidemiology and Genomic Characterization ofJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, we have moved from the sporadic description of terbinafine-resistant (TerR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.